Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SpePharm acquires rights to Savene and partners with Paladin

March 5, 2010

Ixabepilone therapy linked to tumor regression in phase II metastatic renal cell carcinoma trial

March 5, 2010

Light Sciences Oncology completes enrollment in phase III Aptocine trial in MCRC

March 4, 2010

Seattle Genetics achieves milestone under antibody-drug conjugate collaboration with Genentech

March 4, 2010

Celsion to begin phase II trial of ThermoDox and RFA for colorectal liver metastases

March 3, 2010

FDA reschedules meeting on ChemGenex's application for Omapro in CML

March 3, 2010

Synta resumes clinical development of elesclomol

March 3, 2010

Bayer Schering claims new polo-like kinase 1 inhibitors

March 3, 2010

Rigel identifies AXL kinase inhibitors for cancer therapy

March 3, 2010

FDA requests Vion conduct phase II trial of Onrigin in AML prior to phase III study

March 2, 2010

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...